Stockscreener 앱 받기
1.895
13.47%
-0.295
시간 외 거래:
1.90
0.005
+0.26%
Editas Medicine Inc 주식(EDIT)의 최신 뉴스
Editas Medicine SVP Parison sells $957 in stock By Investing.com - Investing.com Australia
Editas Medicine SVP Parison sells $957 in stock - Investing.com
Editas Medicine (NASDAQ:EDIT) CEO Gilmore Neil O'neill Sells 5,394 Shares - MarketBeat
EDIT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Editas Medicine at TD Cowen: Strategic Focus on In Vivo CRISPR - Investing.com Canada
EDIT Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Editas Medicine Inc expected to post a loss of 26 cents a shareEarnings Preview - TradingView
Editas Medicine (EDIT) Expected to Announce Earnings on Wednesday - MarketBeat
Editas Medicine to Participate in Upcoming Investor Conferences - The Manila Times
Editas Medicine, Inc. (NASDAQ:EDIT) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Editas Medicine (NASDAQ:EDIT) Shares Pass Below 50-Day Moving AverageWhat's Next? - MarketBeat
Can Editas Medicine Inc. ride the EV waveQuarterly Profit Report & Weekly Setup with High ROI Potential - mfd.ru
Market Moves: Whats the MACD signal for CARGWeekly Trend Report & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Signal Recap: Can Editas Medicine Inc disrupt its industryBear Alert & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
Aug Movers: Can Editas Medicine Inc. outperform in the next rallyEarnings Risk Report & Reliable Volume Spike Trade Alerts - mfd.ru
Why Editas Medicine Inc. (8EM) stock could be next leaderJuly 2025 Trade Ideas & AI Driven Price Predictions - mfd.ru
Editas Medicine’s Volatile Comeback: Can CRISPR Hype Outrun Clinical Risk? - AD HOC NEWS
Editas Medicine (NASDAQ:EDIT) Share Price Crosses Below Fifty Day Moving AverageTime to Sell? - MarketBeat
Analyst Downgrade: Can Editas Medicine Inc grow without external fundingMarket Performance Summary & Free Long-Term Investment Growth Plans - baoquankhu1.vn
Can Editas Medicine Inc. stock sustain revenue growth2025 Investor Takeaways & Community Shared Stock Ideas - mfd.ru
Can Editas Medicine Inc. disrupt its industryWeekly Gains Report & Daily Momentum Trading Reports - mfd.ru
Companies Like Editas Medicine (NASDAQ:EDIT) Could Be Quite Risky - Yahoo Finance
Gene Editing Market Growth in Future Scope 2026-2033| CRISPR - openPR.com
Editas Medicine (NASDAQ:EDIT) Share Price Crosses Below 50 Day Moving AverageHere's What Happened - MarketBeat
Editas Medicine achieves significant LDL reduction with EDIT-401 therapy - Traders Union
Editas Medicine, Inc. (NASDAQ:EDIT) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Individual investors who hold 55% of Editas Medicine, Inc. (NASDAQ:EDIT) gained 14%, institutions profited as well - simplywall.st
Genome Editing Market Forecast to Reach $23.6 Billion by 2031 Registering 16.6% CAGR: Insights Into Technology and Investment Trends - GlobeNewswire Inc.
Street Watch: Is Editas Medicine Inc stock a falling knife or bargain buy2025 Major Catalysts & Daily Oversold Bounce Ideas - baoquankhu1.vn
Editas Medicine (NASDAQ:EDIT) Stock Crosses Below 50 Day Moving AverageWhat's Next? - MarketBeat
Hedge Fund Bets: Can Editas Medicine Inc disrupt its industry2025 Buyback Activity & Precise Trade Entry Recommendations - baoquankhu1.vn
Fed Watch: Can Editas Medicine Inc. maintain sales growthJuly 2025 Patterns & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Recap Report: Can Editas Medicine Inc. stock surprise with earnings upsidePortfolio Risk Summary & Low Risk Investment Opportunities - Bộ Nội Vụ
Retail Surge: Is Editas Medicine Inc stock affected by interest rate hikesJuly 2025 Decliners & Real-Time Volume Analysis Alerts - Bộ Nội Vụ
Inflation Data: Will Editas Medicine Inc stock remain a Wall Street favoriteJuly 2025 Recap & Detailed Earnings Play Strategies - moha.gov.vn
Is Editas Medicine Inc. stock overvalued by current metricsQuarterly Risk Review & AI Powered Trade Plan Recommendations - ulpravda.ru
Can Editas Medicine Inc. stock surprise with earnings upsideQuarterly Market Summary & Free Safe Entry Trade Signal Reports - Улправда
Will Editas Medicine Inc. stock remain a Wall Street favoriteMarket Sentiment Review & AI Driven Price Predictions - Улправда
Is Editas Medicine Inc. stock in correction or buying zone2025 Growth vs Value & Reliable Entry Point Alerts - Улправда
Can Editas Medicine Inc. stock attract ESG capital inflowsWall Street Watch & Real-Time Buy Signal Notifications - ulpravda.ru
Is Editas Medicine Inc. stock affected by interest rate hikesShort Setup & Reliable Volume Spike Trade Alerts - Улправда
Is Editas Medicine Inc. stock ready for breakout2025 Valuation Update & Free Expert Approved Momentum Trade Ideas - Улправда
Street Watch: Can Editas Medicine Inc. (8EM) stock expand revenue streams2025 Geopolitical Influence & Free Long-Term Investment Growth Plans - Улправда
Aug Catalysts: Why Editas Medicine Inc. (8EM) stock could rally stronglyQuarterly Profit Summary & Free Verified High Yield Trade Plans - Улправда
Gene Editing Tools Market to Reach US$ 1,700.05 million by 2033 | - openPR.com
Editas Medicine, Inc. (NASDAQ:EDIT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Fibonacci Retracement Aligns with Support in Alka Securities LimitedMarket Sentiment Shifts & Free Realize Exceptional Returns - earlytimes.in
Editas Medicine (NASDAQ:EDIT) Stock Price Down 2.9%Should You Sell? - MarketBeat
Editas Medicine (EDIT) price target increased by 22.78% to 4.95 - MSN
Editas Medicine Stock Slides After-Hours On Bigger-Than-Expected Q4 Loss, But Retail Bulls Eye M&A Potential - MSN
Would You Still Hold Editas Medicine Stock If It Fell Another 30%? - Trefis
3.69%
0.68%
자본화:
|
볼륨(24시간):